SCHEMBL3249846

SCHEMBL3249846

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(-c4ccccc4NS(C)(=O)=O)cc3c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MCL1 Q07820 1/20 0.42
NPC1 O15118 1/20 0.41
METAP2 P50579 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
CLEC4M Q9H2X3 1/20 0.39
PARP14 Q460N5 1/20 0.39
CDK1 P06493 1/20 0.39
CDK2 P24941 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
JAK3 P52333 5/20 0.38
JAK2 O60674 4/20 0.38
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
GABRB1 P18505 1/20 0.38
GABRA3 P34903 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3245137 0.87 MCL1 (0.53) MCL1METAP2PARP14CDK1CDK2
SCHEMBL3249063 0.86 CDK2 (0.39) KDM4ETSHRHSD17B10MCL1METAP2
SCHEMBL3251203 0.85 JAK3 (0.47) NPC1CLEC4MJAK3JAK2MMP2
SCHEMBL3245835 0.84 TRPV1 (0.41) KDM4ENPC1ALDH1A1HPGDCLEC4M
SCHEMBL3243112 0.84 CSF1R (0.46) KDM4ENPC1ALDH1A1HPGDCLEC4M
SCHEMBL3254828 0.84 NPC1 (0.45) KDM4EHSD17B10NPC1ALDH1A1CLEC4M
SCHEMBL3253196 0.84 MMP2 (0.53) KDM4EHSD17B10ALDH1A1HPGDMAPK1
SCHEMBL3253889 0.83 CLEC4M (0.47) KDM4EHSD17B10NPC1ALDH1A1HPGD
SCHEMBL3252757 0.82 NPC1 (0.51) KDM4EHSD17B10NPC1ALDH1A1HPGD
SCHEMBL3252056 0.81 NPC1 (0.43) KDM4EHSD17B10NPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 KDM4E 1970/4885TSHR 4040/4885HSD17B10 3847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.